Viral proteins expressed by EBV-associated tumors provide target antigens for immunotherapy. Adoptive T-cell therapy has proven effective for post transplant EBV-associated lymphoma in which all EBV latent antigens are expressed (type III latency). Application of immunotherapeutic strategies to tumors such as nasopharyngeal carcinoma (NPC) and Hodgkin's lymphoma (HL) that have a restricted pattern of EBV antigen expression (type II latency) is under investigation. Potential EBV antigen targets for T-cell therapy expressed by these tumors include latent membrane proteins (LMP) 1 and 2. A broad panel of epitopes must be identified from these target antigens to optimize vaccination strategies and facilitate monitoring of tumor-specific T-cell populations after immunotherapeutic interventions. So far, LMP2 epitopes have been identified for only a limited number of HLA alleles. Using a peptide library spanning the entire LMP2 sequence, 25 CTL lines from patients with EBV-positive malignancies expressing type II latency were screened for the presence of LMP2-specific T-cell populations. In 21 of 25 lines, T-cell responses against 1-5 LMP2 epitopes were identified. These included responses to previously described epitopes as well as to newly identified HLA-A*0206, A*0204/17, A29, A68, B*1402, B27, B*3501, B53 and HLA-DR restricted epitopes. Seven of the 9 newly identified epitopes were antigenically conserved among virus isolates from NPC tumors. These new LMP2-epitopes broaden the diversity of HLA alleles with available epitopes, and in particular those epitopes conserved between EBV strains provide valuable tools for immunotherapy and immune monitoring. 
Introduction
Virtually all undifferentiated NPC, up to 40% of HL and 20-100% of non-Hodgkin lymphomas (NHL) depending on subtype and localization are associated with EBV. [1] [2] [3] [4] Regardless of the role of EBV in the pathogenesis of these malignancies the viral antigens expressed by tumor cells provide target antigens for immunotherapeutic strategies. Adoptive transfer of EBV-specific T-cells has proven an effective strategy to prevent and treat EBV-associated lymphomas that arise in immunocompromised patients. 5, 6 These lymphomas however are highly immunogenic as they express all latent EBV proteins including the nuclear antigens EBNAs -1, -2, -3A, -3B, -3C and -LP and the membrane proteins LMP1 and 2 (type III latency). In contrast, NPC, HL, and NHL tumors do not express the immunodominant EBNA3 antigens and have an EBV antigen expression pattern restricted to EBNA1, LMP1 and LMP2 (type II latency). EBNA1, essential for maintaining the latent genome in dividing cells, is present in all EBVpositive malignancies. However, although antigen processing and presentation has been reported for EBNA1 proteins truncated during translation, [7] [8] [9] an internal glycine-alanine repeat prevents processing of the full-length protein and thereby inhibits its presentation to CD8+ T-cells. [10] [11] [12] LMP1 and LMP2 proteins are present in the majority of EBV-associated NPC and HL tumors and although subdominant antigens, they provide targets for immunotherapeutic approaches. 3, [13] [14] [15] LMP2 and to a lesser extent LMP1-specific T-cells are present in the peripheral blood of patients with EBV-positive HL and NPC. 16, 17 This implies that these malignancies are able to develop despite the presence of circulating tumor-specific T-cells. Secretion of immunosuppressive chemokines and cytokines and the presence of regulatory T-cells at the tumor site may contribute to this escape from immune surveillance. [18] [19] [20] Immunotherapeutic strategies that enhance the LMP-specific immune response may overcome this immunosuppressive environment. LMP-specific T-cells can be actively boosted by vaccination with LMP-peptides. 21, 22 Alternatively, LMP-specific T-cells can be removed from the immunosuppressive environment and expanded ex vivo. EBV-transformed B-cell lines (LCL) provide an excellent source of APC for this purpose and are readily generated from patients with EBV-positive tumors. [23] [24] [25] However, a major concern was whether LMP2-specific T-cells could be reactivated and expanded using LCL s , in which all other latency proteins including the immunodominant EBNA3 antigens are expressed. 17, 26 To further develop and implement such immunotherapeutic strategies detailed characterization of LMP-specific T-cell immunity is required. So far LMP2 epitopes presented in the context of HLA-A2, A11, A23, A24, A25, B27, B60 and B63 have been described. [27] [28] [29] [30] [31] [32] [33] Expansion of this panel of LMP2 epitopes is desirable for multiple reasons. First, this will enable peptide or epitope-based vaccination strategies for all patients regardless of their HLA type. Second, vaccination with multiple rather than a single epitope is desirable to prevent tumor escape as a result of mutation or strain-specific epitope variation. 34 Third, a broad panel of LMP2 epitopes provides useful reagents such as tetramers and peptides that can be used for detailed characterization of ex-vivo expanded LMP2-specific T-cells for adoptive transfer as well as for monitoring of LMP2-directed immune responses following therapeutic intervention.
We were successful in generating EBV-specific CTL lines from 25 patients with type II tumors using LCL as APC. 25, 35 Here we report the detailed epitope specificities of LMP2directed immune responses in these patient CTL lines using a peptide library that spans the entire LMP2 protein. Using this strategy we identified 9 new LMP2-derived HLA class I and class II-restricted epitopes and we demonstrate the utility of these LMP2-eptiopes as reagents for immunological monitoring.
Methods

Patients and EBV status of the tumors
The Baylor College of Medicine Institutional Review Board and the Food and Drug Administration approved the generation of EBV-specific CTL lines for use in clinical studies in patients with EBV-positive NPC, HL and NHL. 25, 35 In all patients, tumor samples had been established as EBV-positive, using immunohistochemistry for LMP-1 and/or in situ hybridization for the small non polyadenylated viral RNA EBER1. 23 Patient CTL lines EBV-specific CTL lines were reactivated and expanded from PBMC using autologous LCL as APC, as described previously. 36 Briefly, after informed consent, peripheral blood (40-60 ml) was collected from patients with EBV-positive NPC, HL and NHL. First, 5x10 6 PBMC were incubated with concentrated supernatants from the EBV producer cell line B95-8, and cultured in RPMI 1640 (Hyclone, Logan, UT) supplemented with 10% FBS (Hyclone, Logan, UT) and 200 mM Glutamine (Gibco, Grand Island NY), in the presence of 1 μg/ml cyclosporin A (Sandoz, Vienna, Austria) to establish an LCL. Subsequently, PBMC (2 x 10 6 per well of a 24 well plate) were stimulated with LCL irradiated (40 Gy) at a responder:stimulator ratio (R:S) of 40:1 in 50%RPMI/50% Clicks media (Irvine, Santa Ana, CA) supplemented with 10% FBS and 200 mM Glutamine. After 9-12 days, viable cells were restimulated with irradiated LCL at a R:S ratio of 4:1 and subsequently further expanded by weekly stimulations with LCL in the presence of recombinant human interleukin-2 (rhIL-2, Proleukin, Chiron Corporation, Emeryville, CA) (40-100 U/ml).
LMP2-peptides
A peptide library consisting of 122 15-mer peptides with 11 amino acids overlap covering the complete sequence of LMP2a (B95-8 strain, swiss prot access P13285) was purchased from Dieter Stoll at Natural and Medical Sciences Institute, University of Tuebingen, Germany. Lyophilized peptides were reconstituted at 20 mg/ml in DMSO. As described previously, these peptides were pooled in a total of 23 pools in such a manner that each 15-mer peptide was represented in 2 pools according to the grid shown in Figure 1b . 37 Single 15-mer peptides were aliquoted at 8 mg/ml. To determine the minimal recognized LMP2 epitope sequence additional peptides, varying in length from 9-14 amino acids, were obtained from Genemed Synthesis Inc. (South San Francisco, CA) and reconstituted at 10 mg/ml in DMSO. Aliquots of peptides were stored at -80°C.
Enzyme-Linked Immunospot (ELISPOT) assay
96-well filtration plates (MultiScreen, #MAHAS4510, Millipore, Bedford, MA) were coated overnight with 10 mg/mL anti-IFN-γ antibody (Catcher-mAB91-DIK, Mabtech, Cincinnati, OH). CTL were plated at 1x10 5 cells/well and stimulated with LMP2 peptide pools (1 μg/mL of each peptide) or individual peptides (5-5000 ng/mL as indicated). Irradiated (40 Gy) autologous LCL were used as positive control. After 18-24 hours, the plates were washed and incubated with the secondary biotin conjugated anti-IFN-γ monoclonal antibody (Detector-mAb (7-B6-1-Biotin), Mabtech). After incubation with Avidin:biotinylated horseradish peroxidase complex (Vectastain Elite ABC Kit (Standard), #PK6100, Vector Laboratories, Burlingame, CA) plates were developed with AEC substrate (Sigma, St. Louis, MO). Plates were sent for evaluation to Zellnet Consulting, New York, NY. Results are shown as spot forming cells (SFC) per 1x10 5 CTL. For the screening with LMP2 peptide pools, all assays were performed once in duplicate. Prior to using this method as screening for patient CTL lines, the reproducibility of this method was first confirmed using CTL lines from 2 healthy donors (data not shown). Those responses that exceeded 5 x times the background level of non-stimulated CTL and were at least 5 SFC/1x10 5 CTL were regarded as significant. For 2 of 25 CTL lines screened this threshold level was lowered to 1x background level. The relevance of the identified LMP2-specific responses was subsequently confirmed in ELISPOT assays using single LMP2 peptides again using a threshold level of 5 x background and > 5 SFC/1x10 5 . Responses to the identified LMP2 epitopes were consistently detected in the CTL lines studied, however, the strength of these responses varied between assays. The average response to each epitope within the same CTL line is reported in Table I .
Determining HLA-restriction of identified epitopes
To determine the HLA-restriction of the novel LMP2 class I peptides, CTL with specificity for the LMP2 peptide, were plated at 1x10 5 /well in an IFN-γ ELISPOT assay with partially HLA-matched phytohemagglutinin (PHA)-activated lymphoblasts (40Gy irradiated) used as antigen presenting cells either alone or pulsed with peptide (10 ug/ml for 30 minutes at 37˚C). All immunogenic peptides were analyzed for the presence of anchor sites for HLA-alleles expressed by the patient using prediction databases from Dr. Kenneth Parker, National Institute of Allergy and Infectious Diseases, NIH (http://bimas.dcrt.nih.gov/molbio/hla_bind/index. html_112601) and Dr. Hans-Georg Rammensee, Heidelberg, Germany (www.syfpeithi.de) and the HLA FactsBook. 38 For 7 out of 9 epitopes the HLA-restriction was subsequently confirmed by staining with the HLA tetramer derived from the newly identifed epitope. To confirm HLAclass II restriction of identified epitopes, T-cells were stained with CD4 and CD8 mAbs (BD Biosciences, San Jose, CA) and sorted on a MoFlow Cytometer and subsequently used in an IFN-γ ELISPOT assay. HLA-DR restriction was confirmed by incubating the T-cells for 30 minutes at 37˚C with HLA-DR blocking antibody (1 μg/well) before addition of the peptide.
Tetramer staining
Tetramers were prepared by the National Institute of Allergy and Infectious Diseases tetramer core facility (Atlanta, GA), or by the Baylor College of Medicine Tetramer Core Facility (Houston, TX). CTL or PBMC (5-10x10 5 ) were incubated at room temperature for 30 minutes in PBS/1% FCS containing the PE-labeled tetrameric complex. Samples were co-stained with anti-CD8 FITC and anti-CD3 PerCP. Appropriate isotype controls were included. Stained cells were fixed in PBS containing 0.5% paraformaldehyde. For each sample, a minimum of 100,000 cells was analyzed using a FACS Calibur with the Cell Quest Software (Becton Dickinson).
Listed are the amino acid sequence of newly identified (in bold) as well as previously described LMP2-epitopes 27, [29] [30] [31] [32] [33] , their location in the LMP2 molecule, HLA-restriction, the number of CTL lines from NPC, HL and NHL patients in which responses to these epitopes were identified and the strength of these responses. When responses to the indicated epitope were found in more than one patient CTL line average response and range are shown. 
Results
LMP2-specific T-cells within patient CTL lines
Using LCL as APC, EBV-specific T-cells were reactivated and expanded from the peripheral blood of 25 patients with EBV type II latency tumors: 13 patients with NPC, 10 patients with HL and 2 patients with NHL. The presence of LMP2-specific and thus tumor-specific T-cells within these patient CTL lines was assessed using a peptide library representing the entire LMP2a sequence (B95-8 strain). In 21 of 25 patient CTL lines LMP2-specific T-cells were detectable in an IFN-γ ELISPOT assay after overnight incubation with each of the peptide pools. This result demonstrates that T-cells specific for a subdominant EBV-antigen can regularly be reactivated using LCL even in patients. An example of one CTL line is shown in Figure 1a : T-cells that produced above background levels of IFN-g were detectable after stimulation with pools 1, 12, 17 and 18. In two patient CTL lines the spontaneous IFN-γ secretion of non-stimulated T-cells resulted in a signal to noise ratio that was too high to detect LMP2-specific T-cell responses.
In two other patient CTL lines none of the peptide pools induced IFN-γ secretion of the T-cells, although incubation with LCL resulted in a measurable response.
Determining minimal recognized LMP2 sequence
Following the initial screening with each of the LMP2-peptide pools the minimal recognized T-cell epitopes were identified. Based on the LMP2-peptide pools that induced IFNγ secretion, individual pentadecamers that were present in 2 of the peptide pools that tested positive were selected: for example pentadecamers 49, 60, 61 and 72 for the patient CTL line shown as example ( Figure 1b ). Stimulation of the T-cells with these single pentadecamers showed that the amino acid sequence of LMP2 that contained the recognized epitope was present in pentadecamers 60 and 61, most likely in the overlapping 11-amino acid sequence of these two adjacent peptides ( Figure 1c ). In total, 35 LMP2-specific T-cell responses were detected, 24 of which were targeted towards LMP2 sequences representing previously described LMP2 epitopes including FLYALALLL, SSCSSCPLSKI, CLGGLLTMV, IEDPPFNSL, LLWTLVVLL, PYLFWLAAI, TYGPVFMSL, GLGTLGAAI, and RRRWRRLTV 27, 29, [31] [32] [33] (Table I ). In 11 CTL lines, the recognized LMP2 sequence did not contain a known LMP2 epitope. The minimal recognized epitope was then identified by testing of the potential nonamers within the overlapping sequence of two adjacent pentadecamers to which responses were detected. For example, within the RLTVCGGIMFL sequence TVCGGIMFL was shown to represent the minimum recognized epitope, whereas RLTVCGGIM and LTVCGGIMF were not recognized by the CTL (Figure 1d ). Using this strategy 7 nonamers representing new LMP2 epitopes were identified (Table I , epitopes in bold). Two of the epitopes identified here (LPVIVAPYL and FTASVSTVV) represent the minimum epitope within regions of LMP2 earlier reported as CD8+ T-cells recognition sites in PBMC of healthy donors. 33 For one epitope, RRLTVCGGIMF (aa 240-250) the minimal recognized sequence consisted of 11 amino acids rather than 9 amino acids, analogous to a previously described LMP2-epitope SSCSSCPLSKI (aa 340-350). Interestingly, this epitope is located within a region that contains four overlapping CD8-epitopes VLVMLVLLILAYRRRWRRLTVCGGIMFL ,VLVMLVLLILAYRRRWRRLTVCGGIMFL, VLVMLVLLILAYRRRWRRLTVCGGIMFL and VLVMLVLLILAYRRRWRRLTVCGGIMFL and one CD4-epitope VLVMLVLLILAYRRRRWRRLTVCGGIMFL. 39 Similarly, ILLARLFLY is located in an epitope hotspot: SSCSSCPLSKILLARLFLYALALLL, SSCSSCPLSKILLARLFLYALALLL and SSCSSCPLSKILLARLFLYALALLL.
HLA-restriction of identified CD8-epitopes
To determine the HLA-restriction of the identified LMP2-epitopes we took advantage of described peptide binding motifs (see: Methods). The HLA type of the patient used as an example is as follows: A*0206, A24, B51, B61 (Figure 2a ). The identified epitope TVCGGIMFL contains a valine at position 2 and a leucine at position 9, which are anchor residues predicted to bind to HLA-A*0206. We subsequently confirmed this HLA-restriction by using partially HLA-matched phytohemagglutinin-activated lymphoblasts pulsed with this LMP2peptide as APC in an ELISPOT assay (Figure 2a) . T-cells secreted IFN-γ upon stimulation with all peptide-pulsed APC matched for the HLA-A2 allele, but not after stimulation with peptide-pulsed APC matched for HLA-A24. As no HLA-A*0206 matched APC were available, A*0201 typed APC were used in this experiment. Comparing IFN-γ secretion upon stimulation with autologous (A*0206) and A*0201-typed APC pulsed with different concentrations of the TVCGGIMFL peptide demonstrates that although less efficient this epitope can also be presented in the context of HLA-A*0201 (Figure 2b) . HLA-A2-restriction was further confirmed by the identification of a T-cell population staining positive with HLA-A*0201-TVCGGIMFL tetramer (Figure 2c ). Using this same strategy the other newly identified LMP2epitopes were found to be HLA-A*0204 or A*0217, HLA-A29, HLA-A68, HLA-B*1402, HLA-B27, HLA-B*3501 and HLA-B53 restricted (Table I ). 
Identification of a CD4-epitope
Although the LMP2 peptide library used in this study was designed to identify HLA class I restricted epitopes with a length of 9-11 amino acids, an HLA class II restricted epitope was identified in one of the patient CTL lines. T-cells present in this CTL line recognized LMP2-sequence DYQPLGTQDQSLYLG (aa 73-87) but none of the shorter (9-14 aa) peptides derived form this pentadecamer (data not shown). Therefore, the pentadecamer appeared to represent the minimum recognized epitope. As the binding groove of MHC class II molecules can accommodate peptides with a length of up to 20 amino acids we reasoned that this LMP2-peptide may be recognized in the context of HLA class II. Indeed, separation of CD4+ and CD8+ T-cells within this polyclonal CTL line demonstrated that this peptide induces a CD4-mediated T-cell response, whereas no CD8+ T-cells were activated (Figure 3a) . The recognized pentadecamer contains anchor residues that are predicted for binding to HLA-DR4 (DYQPLGT-QDQSLYLG) one of the HLA class II alleles of this patient (HLA-DR4/16, DQ 5/7, DP not done).
Complete abrogation of peptide recognition in the presence of an HLA-DR blocking antibody confirmed this predicted HLA-DR restriction (Figure 3b ). Other class II epitopes may have been missed in this study because of the design of the peptide library, which for detection of class II epitopes, should optimally be composed of overlapping 20-mers 39 .
LMP2-epitopes partially conserved in NPC tumors
The LMP2 peptide library used in this study is based on the prototype EBV type I strain B95-8. However, different EBV strains may be present in the tumor depending on the geographical origin of the patient . 40 For these newly identified LMP2 epitopes to be useful for immunotherapy their sequence must be conserved between the B95-8 strain and the EBV strain present in
Figure 3. Identification of an HLA-DR restricted LMP2 epitope (a) The polyclonal CTL line in which a T-cell population specific for LMP2 peptide DYQPLGTQDQSLYLG was identified was sorted for CD4+ and CD8+ T-cells. Subsequently recognition of this epitope by these separated CD4+ and CD8+ T-cells was determined in an IFN-γ ELISPOT assay. (b)
As this epitope contained anchor sites compatible with HLA-DR4, the HLA-restriction of these epitopes was further characterized by blocking the HLA-DR molecules on the APCs prior to loading with the peptide. EBV-specific CTL from this patient were either non-stimulated or stimulated with APC loaded with peptide with and without prior HLA-DR blocking.
the tumor. We compared the amino acid sequence of the newly identified LMP2 epitopes with described LMP2 sequences in EBV isolates from NPC cell lines and biopsy samples 41 . Six of the 9 epitopes were fully conserved, whereas in 3 epitopes one or two mutations were present (Table II) . Analysis of the immunogenicity of these variant epitopes with those derived from the B95-8 sequence shows that recognition of the CD8-restricted epitopes LPVIVAPYL and MGSLEMVPM is disrupted when indicated amino acids are altered (Figure 4a-c) . The altered amino acids likely compromise HLA binding (e.g. proline > leucine mutation at an anchor site for B53 binding of the LPVIVAPYL epitope) or TCR recognition of these epitopes. T-cell responses to variants of the CD4-restricted epitope DYQPLGTQDQSLYLG, although reduced in number, appear to be preserved possibly because MHC class II restricted epitopes are often promiscuous in their binding to HLA molecules (Figure 4c ). Using those LMP2-epitopes that are conserved between viral isolates for immunotherapeutic strategies is preferred so as to allow for their application in large patient groups worldwide.
Assessing the breadth of the LMP2 response EBV-specific CTL reactivated and expanded using LCL as APC contain both CD4+ (mean 7.4%, range 0.1-50.0%) and CD8+ (mean 83.8%, range 39.4-98.8%) T-cells that can potentially recognize multiple LMP2-derived epitopes. Screening the patient CTL lines with the LMP2 peptide pools allows for assessment of the breadth of the LMP2-directed specificity. In 12 CTL lines, detectable LMP2 reactivity was directed against a single epitope, whereas in 9 CTL lines T-cell responses against 2-5 LMP2 epitopes were present. (Table III) In two CTL lines that were known to contain a FLYALALLL-specific T-cell population as determined by tetramer staining, no IFN-γ secreting cells were detected upon stimulation with peptide pools that contained a pentadecamer representing the FLYALALLL sequence (data not shown). This observation suggests that screening with peptide pools may underestimate the true breath Amino acid sequences of the identified LMP2 epitopes as derived from the reference B95-8 strain were compared to the previously described sequences of three NPC tumor cell lines (C15, C18 and C19) as well as 8 fresh EBV isolates from NPC tumors. 41 Variations of the LMP2 response in some cases. An example of a CTL line containing broad LMP2 specificity is shown in Figure 5 . Initial screening with the LMP2 peptide pools indicated recognition of multiple LMP2 sequences (Figure 5a ). Subsequently these responses were mapped to four LMP2-epitopes: the earlier described HLA-A2-restricted FLYALALLL and LLWTLVVL, and the HLA-B27 restricted RRRWRRLTV epitopes and the newly identified HLA-A29-restricted ILLARLFLY epitope (Figure 5b ). The presence of T-cells recognizing multiple epitopes is desirable as this reduces the risk of immune escape by the tumor, and of strain sequence variations. : Table II ) and responses were measured in an IFN-γ ELISPOT assay. Average and standard deviation of CTL stimulated with 500 ng/ml peptide are shown.
Monitoring of LMP2-specific T-cell populations post adoptive T-cell therapy
The ability to monitor the frequency of LMP2-specific T-cell populations in the peripheral blood or infiltrating at the tumor site is crucial to determine the efficacy of immunotherapeutic interventions. In our ongoing Food and Drug Administration-approved clinical studies, patients with relapsed EBV-positive NPC, HD and NHL are being treated with autologous EBV-specific CTL. LMP2-specific T-cell populations are identified in the infusion product by screening with the LMP2 peptide library and subsequent staining with tetramers derived from the identified epitopes. For example, 11.0% of the CD8+ T-cells within the CTL line from a patient with EBV-positive Hodgkin's disease were specific for one of the newly described LMP2 epitope MGSLEMVPM which was found to be HLA-B*3501-restricted. Following infusion of this EBV-specific CTL line, the LMP2-specific T-cell population was monitored in peripheral blood using tetramer analysis ( Figure 6 ). Pre infusion, 1.98% of CD8+ T-cells in the peripheral blood were specific for this LMP2-epitope. The frequency of MGSLEMVPM-specific T-cells increased to 5.37% six weeks post CTL infusion. These results indicate that the infused CTL (4x10 7 /m 2 ) proliferate and persist for at least 6 weeks post infusion and demonstrate the value of monitoring tools derived from LMP2-epitopes. 
Discussion
Detailed characterization of LMP2-directed T-cell specificity will greatly enhance the potential application of immunotherapeutic strategies and our ability to evaluate their effect as treatment of EBV latency type II malignancies. Stimulation of patient EBV-specific Cytotoxic T-cell lines with an LMP2-peptide library using IFN-γ secretion as read-out proves to be a fast and sensitive method to evaluate the strength and breadth of the LMP2-specific immune response. As this technique is effective regardless of the patient's HLA type, it can be applied to all patients. LMP2-specific T-cell responses were detectable in 84% of LCL-reactivated CTL lines. This result may be viewed as surprising as these patients have developed EBV-positive malignancies in the presence of a competent immune system. However, EBV+ve tumors expressing type II latency, use multiple strategies to evade the immune response. For example, Hodgkin Lymphoma cells secrete the immunosuppressive cytokine, TGFβ, and recruit regulatory T-cells, which together have devastating effects on CTL proliferation and function. 42 The apparent lack of efficacy of endogenous tumor-specific CTL circulating in the patient peripheral blood provides a rationale for ex vivo expansion of the tumor-specific CTL in isolation from tumor-derived immune suppressive factors.
The LMP2-specific T-cell responses were mapped to previously described epitopes and to 9 newly identified HLA class I and class II restricted epitopes. The latter were shown to be HLA-A*0204/17, A*0206, A29, A68, B*1402, B27, B*3501, B53 and DR (likely DR4)-restricted, mostly alleles for which no LMP2-epitopes have previously been identified. Interestingly, the new class II epitope identified, which partially overlaps with a previously reported CD8+ recognition site 33 , and the class I epitope MGSLEMVPM identified in this study, are the only LMP2 epitopes located in the cytoplasmic region of LMP2, whereas all other LMP2 epitopes are located in the transmembrane region. (Figure 7 )
Figure 7. Location of epitopes with the LMP2 molecule
The location of newly identified (in black) and previously described (in gray) CD4-and CD8-epitopes within the LMP2 molecule is shown. Note that the amino acid sequences of multiple epitopes including the newly identified LPVIVAPYL, FTASVSTVV, RRLTVCGGIM, TVCGGIMFL and ILLARLFLY epitopes partially overlap with the sequences of other LMP2 epitopes.
Although NPC, HL and NHL occur worldwide, NPC is endemic in Southern China, 43 whereas EBV-positive HL is more common among Hispanics. 44 As HLA-A*0206 is a common HLA-allele in the Asian population and HLA-A29, A68 and B*3501 are common HLA-alleles among the Hispanic populations 45 these are valuable additions to the panel of LMP2-epitopes particularly when conserved among geographically separated virus isolates.
Initial methods to identify LMP2 epitopes relied on the generation of CTL clones expanded from LCL-reactivated T-cell lines from healthy donors; a relatively time-consuming process. 27, 29, 30 More recently, an epitope screening strategy based on a peptide library developed by Kern et al 37 was used to analyze EBNA1, LMP1 and LMP2-specific immune responses in the peripheral blood of healthy donors. 33, 39 This method with IFN-γ release as measured in an ELISPOT assay as read-out significantly simplified the epitope identification and was therefore our method of choice. LCL-reactivated T-cell lines, increased the frequency of the LMP2-specific T-cells compared to that in PBMC. Nevertheless, LMP2-specificity could rarely be detected in cytotoxicity assays because of the low frequency of the LMP2-specific component. However, LMP2 tetramer reactive cells that were isolated and expanded demonstrated LMP2-specific cytotoxic effector function (not shown). Here we have shown that, using LCL as APC, LMP2-specific T-cells can be reactivated and expanded for the vast majority of patients with type II latency malignancies irrespective of the patient's age, sex, type of cancer, and disease stage. LMP2-specific T-cell populations that represent <0.1% of CD3+ T-cells could be detected using the ELISPOT assay suggesting under detection of LMP2 specificity in previous studies.
One potential problem with the screening method used is that not all epitopes may be detected using the 15-mer peptide pools. In two CTL lines that contained a FLYALALLL -specific T-cell population detectable by tetramer staining, no IFN-γ secreting cells were detected upon stimulation with peptide pools that contained a pentadecamer containing the FLYALALLL sequence. However, upon stimulation with the minimum 9-mer peptide IFN-γ secretion was induced. The pentadecamers used in this study are C-and/or N-terminus extended versions of potential CD8-epitopes. Whereas peptide trimming by aminopeptidases is sufficient for MHC class I presentation of N-terminus extended epitopes, proteosomes are required for presentation of C-terminus extended epitopes. [46] [47] [48] The FLYALALLL-epitope differs from the other epitopes described, in that it relies on the immunoproteasome for its processing from whole antigen. 29 Although T-cells appear to be capable of peptide trimming to a certain extent, it is not clear whether they can express the immunoproteasome after IFN-γ induction, 49, 50 and thus may be unable to complete C-terminal trimming of the FLYALALLL epitope. Therefore, the absence of professional APC in our screening assay may explain why FLYALALLL-specific T-cell responses were not detected in all cases. In addition, when APC are exposed to peptide cocktails competition for binding to HLA molecules may lead to underdetection of LMP2-specificity.
If T-cells specific for LMP2 epitopes are to have anti-tumor effects, epitopes originating from the Caucasian derived B95-8 variant of LMP2, 51 must be conserved in the tumor strain of EBV. Comparison of the LMP2 epitope sequences in B95-8 with Asian and Mediterranean EBV isolates from NPC tumors showed that one or two amino acids were altered in 3 of the newly identified epitopes. Similarly, previous analysis showed amino acid alterations in 6 of 11 described/predicted LMP2 epitopes (including LPVIVAPYL characterized in this paper) in isolates from NPC and HL tumors. 30, 52 We and others 30 have shown that for 5 of these epitopes the alterations did not disrupt CTL recognition. Mutations in 2 epitopes (LPVIVA-PYL and MGSLEMVPM) were shown to compromise their interaction with CTL, and for one epitope (RRRWRRLTV) CTL recognition is predicted to be decreased. 52 Overall, the majority of but not all LMP2 epitopes appear to be antigenically conserved among different isolates.
These results imply that one should ideally use the LMP2 protein as expressed in the tumor as source of antigen for immunotherapeutic strategies. However, as this is not feasible in the manufacturing of a clinical grade therapeutic product, multiple LMP2 epitopes including isolate-specific variant epitopes should be used to activate tumor-specific T-cells.
The ability of tumor cells to delete certain antigens or epitopes to escape from the immune response as described both for the melanoma antigen MART1 and an immunodominant HLA-A11 restricted EBV EBNA3 epitope, further stresses the importance of targeting multiple tumor epitopes preferentially from multiple tumor antigens. 34, 53 Although broad LMP2specificity was found in a number of the LCL-reactivated CTL lines studied, in a significant number of CTL lines the LMP2 response was targeted towards a single epitope and 4 CTL lines lacked detectable numbers of LMP2-specific T-cells. LMP1-specific responses were only detected in 1 out of 25 CTL lines (data not shown). This is most likely a result of the preferential activation of immunodominant EBNA3 and lytic EBV-antigen specific T-cells using LCL as APC to establish these CTL lines. To improve tumor-antigen reactivity, reactivation and expansion methods using APC overexpressing LMP1 and LMP2 have been developed. Using this approach, the frequency of LMP-specific T-cells and the number of epitopes these are targeted towards can be increased. 54, 55 Similarly, for vaccination approaches, vectors encoding whole protein or, to avoid possible oncogenicity of the antigen, multiple LMP1 and LMP2 epitopes (polytope approach) are being developed instead of single peptides, to boost LMP-specific T-cells with a broad specificity. 21 Incorporation of the here-identified LMP2-epitopes into current polytopes, will enhance the number of tumor antigen-derived epitopes targeted and allow for application of this strategy to an even broader patient group.
Valuable tools for immune monitoring following immunotherapeutic interventions can be derived from LMP2-epitopes. These include tetramers and peptides for stimulation of T-cells in quantitative and functional assays to detect cytokine secretion, and here we have demonstrated how the expansion and persistence of LMP2-specific T-cells can be monitored in the peripheral blood using LMP2-tetramers. Such immune studies that provide insight into functional changes in tumor immunity are crucial to evaluate efficacy and further optimize immunotherapeutic strategies. These newly identified LMP2 epitopes will contribute to a detailed characterization of the LMP2-directed T-cell immunity required to achieve this goal.
